HUP0101432A2 - Rák kezelésére és megelőzésére alkalmas peptidek - Google Patents

Rák kezelésére és megelőzésére alkalmas peptidek

Info

Publication number
HUP0101432A2
HUP0101432A2 HU0101432A HUP0101432A HUP0101432A2 HU P0101432 A2 HUP0101432 A2 HU P0101432A2 HU 0101432 A HU0101432 A HU 0101432A HU P0101432 A HUP0101432 A HU P0101432A HU P0101432 A2 HUP0101432 A2 HU P0101432A2
Authority
HU
Hungary
Prior art keywords
peptides
gene
cancer
subject
dna sequences
Prior art date
Application number
HU0101432A
Other languages
English (en)
Inventor
Jon Amund Eriksen
Gustav Gaudernack
Marianne Klemp Gjertsen
Mona Moller
Ingvil Saeterdal
Original Assignee
Norsk Hydro Asa.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norsk Hydro Asa. filed Critical Norsk Hydro Asa.
Publication of HUP0101432A2 publication Critical patent/HUP0101432A2/hu
Publication of HUP0101432A3 publication Critical patent/HUP0101432A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A találmány tárgya legalább 8 aminosav hosszúságúpeptid, amely daganatsejtgénben, előnyösen BAX-génben, TGF<RII-génbenvagy egyéb, rák keletkezésével összefüggő génben létrejöttkereteltolódásos mutáció eredményeként keletkezett mutáns fehérjefragmense, és vagy teljes hosszúságú vagy antigén-bemutató sejt általvégzett feldolgozását követően elnyert alakjában T-sejtesválaszreakció kiváltására képes. A találmány tárgyát képezik továbbá apeptideket kódoló DNS-szekvenciák és vektorok és a peptideket vagy aDNS-szekvenciákat tartalmazó gyógyászati készítmények ésdaganatellenes vakcinák. A találmány tárgya továbbá daganatosmegbetegedésre hajlamos vagy abban szenvedő személy vakcinázására vagykezelésére, valamint a peptidek azonosítására szolgáló eljárás. Atalálmány szerinti megoldás alkalmas génjeikben végbementkereteltolódásos mutációk miatt kialakult daganatos megbetegedésekbenszenvedők gyógykezelésére és ilyen betegségek megelőzésére. Ó
HU0101432A 1998-05-08 1999-05-03 Peptides that ellicit, cellular immunity HUP0101432A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO19982097A NO315238B1 (no) 1998-05-08 1998-05-08 Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
PCT/NO1999/000143 WO1999058552A2 (en) 1998-05-08 1999-05-03 Peptides that ellicit t, cellular immunity

Publications (2)

Publication Number Publication Date
HUP0101432A2 true HUP0101432A2 (hu) 2001-08-28
HUP0101432A3 HUP0101432A3 (en) 2004-01-28

Family

ID=19902021

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0101432A HUP0101432A3 (en) 1998-05-08 1999-05-03 Peptides that ellicit, cellular immunity

Country Status (13)

Country Link
US (4) US6759046B1 (hu)
EP (2) EP2374814B1 (hu)
JP (1) JP4591983B2 (hu)
CN (1) CN100355781C (hu)
AR (1) AR018346A1 (hu)
AU (1) AU755712B2 (hu)
CA (1) CA2327549C (hu)
ES (1) ES2463825T3 (hu)
HK (1) HK1036997A1 (hu)
HU (1) HUP0101432A3 (hu)
NO (1) NO315238B1 (hu)
PL (1) PL344341A1 (hu)
WO (1) WO1999058552A2 (hu)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO314086B1 (no) 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
NO315238B1 (no) * 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
GB2361701A (en) * 2000-04-28 2001-10-31 Norsk Hydro As DNA polymerase delta mutants
GB0031430D0 (en) 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides
CA2471735A1 (en) * 2001-08-29 2003-03-13 Kyogo Itoh Desensitizers
EP1369126A1 (en) * 2002-04-18 2003-12-10 MTM Laboratories AG Use of coding microsatellite region frameshift mutation-derived peptides for treating cancer
AU2003232485A1 (en) 2002-04-18 2003-10-27 Mtm Laboratories Ag Neopeptides and methods useful for detection and treatment of cancer
US20050221350A1 (en) * 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
ES2676503T3 (es) * 2002-12-16 2018-07-20 Globeimmune, Inc. Vacunas basadas en levadura como inmunoterapia
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
WO2006029343A2 (en) * 2004-09-07 2006-03-16 The Burnham Institute Peptides that selectively home to heart vasculature and related conjugates and methods
US7501486B2 (en) * 2004-09-07 2009-03-10 Burnham Institute For Medical Research Peptides that selectively home to heart vasculature and related conjugates and methods
BRPI0516356A (pt) 2004-10-18 2008-09-02 Globeimmune Inc terapia à base de levedura para infecções crÈnicas da hepatite c
CA2614884A1 (en) * 2005-07-11 2007-01-18 Globeimmune, Inc Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
US20090186042A1 (en) * 2006-02-27 2009-07-23 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
ES2709176T3 (es) 2006-08-11 2019-04-15 Life Sciences Res Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
KR20100015661A (ko) * 2007-03-19 2010-02-12 글로브이뮨 암의 표적 치료법의 돌연변이성 이탈의 표적 절제를 위한 조성물 및 방법
US20080293050A1 (en) * 2007-05-25 2008-11-27 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Gene analysis for determination of a treatment characteristic
EP2623115A1 (en) * 2008-02-14 2013-08-07 Life Sciences Research Partners VZW Immunogenic control of tumours and tumour cells
EP3075391A1 (en) * 2008-02-14 2016-10-05 Life Sciences Research Partners VZW Strategies to prevent and/or treat immune responses to soluble allofactors
EP2623124A1 (en) 2008-02-14 2013-08-07 Life Sciences Research Partners VZW Elimination of immune responses to viral vectors
CA2715517C (en) * 2008-02-14 2018-07-24 Life Sciences Research Partners Vzw Immunogenic peptides and their use in preventing or treating allograft rejection
ES2545886T3 (es) 2008-02-14 2015-09-16 Life Sciences Research Partners Vzw Inmunoterapia dirigida a patógenos intracelulares
WO2009101207A1 (en) 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Cd4+ t-cells with cytolytic properties
WO2010033841A1 (en) 2008-09-19 2010-03-25 Globeimmune, Inc. Immunotherapy for chronic hepatitis c virus infection
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
KR20110136825A (ko) 2009-03-09 2011-12-21 바이오아트라, 엘엘씨 미락 단백질
US10023847B2 (en) 2010-11-25 2018-07-17 Imnate Sarl Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
BR112014009176B1 (pt) * 2011-10-28 2022-08-30 Oncotherapy Science, Inc Composição para indução de linfócito t citotóxico (ctl), uso no tratamento e profilaxia de câncer e indução de resposta imune contra câncer e métodos in vitro para indução de ctl
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
EP2834264A1 (en) * 2012-04-04 2015-02-11 Yeda Research and Development Co. Ltd. Lipopeptide conjugates comprising sphingolipid and hiv gp41 derived peptides
JP5890769B2 (ja) * 2012-12-13 2016-03-22 ループレヒト−カルルス・ウニヴェルジテート・ハイデルベルクＲｕｐｒｅｃｈｔ−Ｋａｒｌｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈｅｉｄｅｌｂｅｒｇ がんの予防及び治療のためのｍｓｉ特異的なフレームシフトペプチド（ｆｓｐ）
US9205140B2 (en) 2012-12-13 2015-12-08 Ruprecht-Karls-Universität MSI-specific frameshift peptides (FSP) for prevention and treatment of cancer
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
WO2016085904A1 (en) * 2014-11-26 2016-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mutated kras t cell receptors
MA42420A (fr) 2015-05-13 2018-05-23 Agenus Inc Vaccins pour le traitement et la prévention du cancer
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
JP2016028025A (ja) * 2015-07-29 2016-02-25 ループレヒト−カルルス・ウニヴェルジテート・ハイデルベルクＲｕｐｒｅｃｈｔ−Ｋａｒｌｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈｅｉｄｅｌｂｅｒｇ がんの予防及び治療のためのｍｓｉ特異的なフレームシフトペプチド（ｆｓｐ）
CN108289941B (zh) 2015-09-25 2022-06-21 易姆赛斯股份公司 用于消除对治疗剂的免疫应答的改进的方法和化合物
AU2016340763B2 (en) * 2015-10-23 2021-04-22 Jai Prakash Integrin binding peptides and uses thereof
EP3400004A1 (en) 2016-01-08 2018-11-14 Vaccibody AS Therapeutic anticancer neoepitope vaccine
EP3779447B1 (en) * 2016-03-15 2023-02-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to activate the anti-tumoral cd8+t cell response of a patient affected with a cancer
CN109069605B (zh) 2016-04-19 2022-11-29 易姆赛斯股份公司 新免疫原性CD1d结合肽
GB201608052D0 (en) * 2016-05-09 2016-06-22 Univ Oslo Hf T-cell receptors which recognise frameshift mutants of TGF-beta RII
WO2018039302A1 (en) * 2016-08-23 2018-03-01 The Cleveland Clinic Foundation Cancer treatment using cx26 blocking peptides
WO2018157773A1 (zh) * 2017-02-28 2018-09-07 暨南大学 一种促进创伤后组织修复与再生的修复肽及其应用
CN108503690B (zh) * 2017-02-28 2020-07-03 暨南大学 一种促进创伤后组织修复与再生的修复肽及其应用
WO2018223092A1 (en) 2017-06-02 2018-12-06 Arizona Board Of Regents On Behalf Of Arizona State University A method to create personalized cancer vaccines
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
MA52363A (fr) 2018-04-26 2021-03-03 Agenus Inc Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
WO2020022901A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for uterine cancer
CA3106564A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
EP3827265A1 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Cancer vaccines for kidney cancer
EP3827264A1 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Arid1a, cdkn2a, kmt2b, kmt2d, tp53 and pten vaccines for cancer
WO2020022902A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for colorectal cancer
PL3840767T3 (pl) * 2019-05-29 2024-03-04 Hubro Therapeutics As Peptydy
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
CN110734474B (zh) * 2019-11-29 2021-10-19 中山大学 一种抗菌肽的筛选方法及其应用
CN113061165A (zh) * 2020-01-02 2021-07-02 厦门大学 EB病毒BNLF2b基因编码多肽及其检测用途
WO2021142007A1 (en) * 2020-01-09 2021-07-15 Arizona Board Of Regents On Behalf Of Arizona State University Antibodies and method of producing antibodies
WO2021239980A2 (en) * 2020-05-28 2021-12-02 Hubro Therapeutics As A peptide cocktail
WO2024052542A2 (en) * 2022-09-09 2024-03-14 Hubro Therapeutics As A peptide cocktail

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
US5700638A (en) * 1993-08-26 1997-12-23 Washington University Cell death regulator
GB9410922D0 (en) 1994-06-01 1994-07-20 Townsend Alain R M Vaccines
JPH10510988A (ja) 1994-12-14 1998-10-27 ザ スクリップス リサーチ インスティテュート 腫瘍−特異的細胞毒性ｔ細胞のインビボ活性化
US5866323A (en) * 1995-04-07 1999-02-02 Case Western Reserve University Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors
WO1997012992A2 (en) 1995-10-02 1997-04-10 Royal Netherlands Academy Of Arts And Sciences Diagnosis method for a disease caused by a frameshift mutation in a gene and reagents therefore
US5973018A (en) * 1995-10-04 1999-10-26 Owens-Corning Fiberglas Technology, Inc. Process for producing shaped phenolic foams
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
AU4907797A (en) 1996-10-10 1998-05-05 Wistar Institute Of Anatomy And Biology, The Methods and compositions for inducing a protective immune response to cancers
GB2328689A (en) * 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO314086B1 (no) * 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
NO315238B1 (no) * 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
GB0031430D0 (en) * 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides

Also Published As

Publication number Publication date
EP1078000A2 (en) 2001-02-28
ES2463825T3 (es) 2014-05-29
HK1036997A1 (en) 2002-01-25
JP4591983B2 (ja) 2010-12-01
WO1999058552A3 (en) 2000-03-02
US20070004632A1 (en) 2007-01-04
EP2374814B1 (en) 2014-03-19
US7863244B2 (en) 2011-01-04
US6759046B1 (en) 2004-07-06
AR018346A1 (es) 2001-11-14
EP1078000B1 (en) 2017-03-29
CN1305495A (zh) 2001-07-25
WO1999058552A2 (en) 1999-11-18
NO982097L (no) 1999-11-09
EP2374814A2 (en) 2011-10-12
CN100355781C (zh) 2007-12-19
CA2327549C (en) 2014-10-07
NO315238B1 (no) 2003-08-04
US20050074849A1 (en) 2005-04-07
JP2002519999A (ja) 2002-07-09
CA2327549A1 (en) 1999-11-18
AU755712B2 (en) 2002-12-19
EP2374814A3 (en) 2012-01-11
NO982097D0 (no) 1998-05-08
AU5451699A (en) 1999-11-29
US8614177B2 (en) 2013-12-24
HUP0101432A3 (en) 2004-01-28
PL344341A1 (en) 2001-11-05
US7192927B2 (en) 2007-03-20
US20110105721A1 (en) 2011-05-05

Similar Documents

Publication Publication Date Title
HUP0101432A2 (hu) Rák kezelésére és megelőzésére alkalmas peptidek
HUP0101734A2 (hu) Béta-amiloid prekurzor protein és ubiquitin-B kereteltolódásos mutánsok és alkalmazásuk
HUP0203409A2 (hu) Gamma-interferon-konjugátumok
NZ551802A (en) A hyperimmune serum-reactive antigen consisting of a polypeptide comprising an amino acid sequence in SEQ ID NO:422 and antigenic fragments thereof
AU6576800A (en) Use of a polypeptide for detecting, preventing or treating pathological condition associated with a degenerative, neurological or autoimmune disease
HUP0301829A2 (hu) A nogo-géneknek megfelelő nukleotid- és aminosav-szekvenciák, valamint az ezeken alapuló eljárások
HUP0202882A2 (en) Novel b7-4 molecules and uses therefor
CA2414772A1 (en) Prevention and treatment of alzheimer&#39;s disease
NZ223506A (en) Tissue factor protein, dna encoding it, vectors, host cells, production of the protein and pharmaceutical compositions
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
DK1025237T3 (da) Human kontrolpunktskinase, hCDS1, præparater og fremgangsmåder
CN109438570B (zh) 肿瘤相关基因fgfr3突变短肽及其应用
ZA966127B (en) Variants of the p53 protein and therapeutic uses.
DK1536006T3 (da) Cancerantigener og anvendelse deraf
HUP0300054A1 (hu) Daganatspecifikus állati fehérjék
HUP0100267A2 (hu) Helicobacter pylori eredetű nukleinsav- és aminosav-szekvenciák és a megfelelő nukleinsavakat vagy peptideket tartalmazó vakcina-készítmények
ES2316191T3 (es) Nueva proteina antigenica tumoral sart-3 y peptido antigenico tumoral de la misma.
CN116970058B (zh) 针对tp53基因r249s突变的肿瘤新抗原多肽及其应用
HK1002284A1 (en) Novel implant and novel vector for the treatment of acquired diseases
PT871757E (pt) Vectores virais condicionalmente replicantes e sua utilizacao
DE69924877D1 (en) Humanes akt-3 protein
RU2003129163A (ru) Полинуклеотид, который можно использовать для модулирования пролиферации раковых клеток
BR0008917A (pt) Compostos
ATE239502T1 (de) Impfung mit peptiden von mhc klasse ii molekülen zur behandlung von autoimmunkrankheiten
WO2003052377A9 (en) 41 human secreted proteins

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees
NF4A Restoration of patent protection
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished